REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
03/23/2026
Back to search
Official data from USPTO
IFOM
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
50
Latest update
03/24/2026
Trademark type
Combined
Nice classes
5, 42, 44
Filing date
09/20/2018
Registration date
03/23/2021
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/23/2021
Last transaction
03/24/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
12
Owner location
IT
Examiner
EBAUGH, MICHAEL
Law office
L80
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the wording "IFOM" in special characters and underlined by a line. Moreover, a stylized representation of a microscope starts from the line and partially overlaps with the letter "O".
Holders and representatives
Holders
I. M. (pessoa física)
Representatives
KENNETH F FLOREK FLOREK & ENDRES PLLC
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for use in dermatology; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for use in hematology; pharmaceutical preparations for the prevention of disorders of the skeletal system; pharmaceutical preparations for treating respiratory diseases; pharmaceutical preparations for the treatment of disorders of the central nervous system related to canceraging and metabolic diseases; pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical preparations for the treatment of disorders of the circulatory system related to aging; pharmaceutical preparations for the treatment of kidney disorders; pharmaceutical preparations for the treatment of hormonal disorders and diabetes; pharmaceutical cough preparations; preparations for treating colds; pharmaceutical preparations for the treatment of flu and headache; pharmaceutical preparations for the treatment of stomach disorders; pharmaceutical preparations for the treatment of digestive diseases; pharmaceutical preparations for treating muscular and/or rheumatological diseases; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical preparations for treating allergies; pharmaceutical agents affecting metabolism; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the treatment of eye diseases; pharmaceutical preparations for use in oncology; diagnostic preparations and reagents for medical use in a clinic or medical laboratory; hormones; dietetic substances adapted for medical usein particularnutritional supplementsvitamin preparationsherbal supplements and preparationsnutritional drink mixes for use as meal replacements for medical usemeal replacement snacks for medical purposes; food and drinks for babiesinfant formula and dietetic products for invalidsin particular food for babiespowdered milk for babiesfoods for enteral feedings and dietetic foods adapted for medical purposes
Class 42
Scientific and technological servicesscientific researchanalysistestingdiagnosis and screening in the field of oncology and cancer research; research and development in the field of oncologyaging and metabolic diseases; scientific and industrial research and analysis servicesscientific researchanalysistesting in the field of medicine; biological research and analysis; scientificclinical and medical research in the field of radiologychemotherapypharmacotherapycoronary artery bypass surgery; basic and clinical research in the field of geneticsstem cellimmunodeficiency and neurodegenerative diseasesproteomicsbioinformaticsneurobiology and molecular biology and diabetes; scientific research in the field of medicine; consultancy in the field of scientific analysis; none of the foregoing to include educational testing
Class 44
Medical serviceshealth care services in the field of oncologyaging and metabolic diseasesmedical assistancephysical rehabilitation in the field of oncology; hospital services; consulting services in the field of medical careconsultancy in the field of medical diagnosismedical analysis and RNA or DNA analysis for cancer diagnosis and prognosis; consulting services relating to health care
Publications
History of USPTO decisions and trademark events.
50 publications found
NREP
NEW REPRESENTATIVE AT IB RECEIVED
05/28/2023
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
08/14/2021
XXSS
GENERIC MADRID TRANSACTION SENT TO IB
07/01/2021
XXCR
GENERIC MADRID TRANSACTION CREATED
07/01/2021
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/23/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
03/23/2021
TMBN
TTAB RELEASE CASE TO TRADEMARKS
02/16/2021
OP.T
OPPOSITION TERMINATED NO. 999999
02/16/2021
OP.D
OPPOSITION DISMISSED NO. 999999
02/16/2021
RFNP
REFUSAL PROCESSED BY IB
12/26/2020
OP.I
OPPOSITION INSTITUTED NO. 999999
12/07/2020
OPNS
OPPOSITION NOTICE (IB REFUSAL) SENT TO IB
12/01/2020
OPNC
OPPOSITION NOTICE (IB REFUSAL) CREATED
12/01/2020
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
10/10/2020
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
09/23/2020
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
09/23/2020
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
06/30/2020
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/02/2020
PUBO
PUBLISHED FOR OPPOSITION
06/02/2020
GPNX
NOTIFICATION PROCESSED BY IB
05/29/2020
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
05/13/2020
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
05/13/2020
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/13/2020
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/24/2020
XAEC
EXAMINER'S AMENDMENT ENTERED
04/17/2020
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
04/17/2020
GNEA
EXAMINERS AMENDMENT E-MAILED
04/17/2020
CNEA
EXAMINERS AMENDMENT -WRITTEN
04/17/2020
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
04/17/2020
PBSR
WITHDRAWN FROM PUB - SENIOR ATTORNEY REQUEST
12/18/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/11/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
12/10/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
12/10/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
12/10/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
12/10/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/18/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/18/2019
ALIE
ASSIGNED TO LIE
11/18/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/12/2019
RFNT
REFUSAL PROCESSED BY IB
06/22/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
05/31/2019
RFRR
REFUSAL PROCESSED BY MPU
05/31/2019
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
05/08/2019
CNRT
NON-FINAL ACTION WRITTEN
05/07/2019
MAFR
APPLICATION FILING RECEIPT MAILED
05/04/2019
DOCK
ASSIGNED TO EXAMINER
04/30/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
04/30/2019
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
04/29/2019
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
04/18/2019
Continuous trademark protection
Get notified about every new filing that threatens IFOM or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.